• 1
    Burnstock, G., Physiology and pathophysiology of purinergic neurotransmission. Physiol. Rev. 2007. 87: 659797.
  • 2
    Yegutkin, G. G., Nucleotide- and nucleoside-converting ectoenzymes: important modulators of purinergic signalling cascade. Biochim. Biophys. Acta 2008. 1783: 673694.
  • 3
    Stagg, J. and Smyth, M. J., Extracellular adenosine triphosphate and adenosine in cancer. Oncogene 2010. 29: 53465358.
  • 4
    Sitkovsky, M. V., Lukashev, D., Apasov, S., Kojima, H., Koshiba, M., Caldwell, C., Ohta, A. and Thiel, M., Physiological control of immune response and inflammatory tissue damage by hypoxia-inducible factors and adenosine A2A receptors. Annu. Rev. Immunol. 2004. 22: 657682.
  • 5
    Resta, R., Yamashita, Y. and Thompson, L. F., Ecto-enzyme and signaling functions of lymphocyte CD73. Immunol. Rev. 1998. 161: 95109.
  • 6
    Airas, L., Salmi, M. and Jalkanen, S., Lymphocyte-vascular adhesion protein-2 is a novel 70-kDa molecule involved in lymphocyte adhesion to vascular endothelium. J. Immunol. 1993. 151: 42284238.
  • 7
    Colgan, S. P., Eltzschig, H. K., Eckle, T. and Thompson, L. F., Physiological roles for ecto-5′-nucleotidase (CD73). Purinergic Signal. 2006. 2: 351360.
  • 8
    Ring, S., Enk, A. H. and Mahnke, K., ATP activates regulatory T Cells in vivo during contact hypersensitivity reactions. J. Immunol. 2010. 184: 34083416.
  • 9
    Kobie, J. J., Shah, P. R., Yang, L., Rebhahn, J. A., Fowell, D. J. and Mosmann, T. R., T regulatory and primed uncommitted CD4 T cells express CD73, which suppresses effector CD4 T cells by converting 5′-adenosine monophosphate to adenosine. J. Immunol. 2006. 177: 67806786.
  • 10
    Mandapathil, M., Hilldorfer, B., Szczepanski, M. J., Czystowska, M., Szajnik, M., Ren, J., Lang, S. et al., Generation and accumulation of immunosuppressive adenosine by human CD4+CD25highFOXP3+regulatory T cells. J. Biol. Chem. 2010. 285: 71767186.
  • 11
    Deaglio, S., Dwyer, K. M., Gao, W., Friedman, D., Usheva, A., Erat, A., Chen, J. F. et al., Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J. Exp. Med. 2007. 204: 12571265.
  • 12
    Airas, L., Hellman, J., Salmi, M., Bono, P., Puurunen, T., Smith, D. J. and Jalkanen, S., CD73 is involved in lymphocyte binding to the endothelium: characterization of lymphocyte-vascular adhesion protein 2 identifies it as CD73. J. Exp. Med. 1995. 182: 16031608.
  • 13
    Thompson, L. F., Eltzschig, H. K., Ibla, J. C., Van De Wiele, C. J., Resta, R., Morote-Garcia, J. C. and Colgan, S. P., Crucial role for ecto-5′-nucleotidase (CD73) in vascular leakage during hypoxia. J. Exp. Med. 2004. 200: 13951405.
  • 14
    Takedachi, M., Qu, D., Ebisuno, Y., Oohara, H., Joachims, M. L., McGee, S. T., Maeda, E. et al., CD73-generated adenosine restricts lymphocyte migration into draining lymph nodes. J. Immunol. 2008. 180: 62886296.
  • 15
    Reutershan, J., Vollmer, I., Stark, S., Wagner, R., Ngamsri, K. C. and Eltzschig, H. K., Adenosine and inflammation: CD39 and CD73 are critical mediators in LPS-induced PMN trafficking into the lungs. FASEB J. 2009. 23: 473482.
  • 16
    Hart, M. L., Much, C., Gorzolla, I. C., Schittenhelm, J., Kloor, D., Stahl, G. L. and Eltzschig, H. K., Extracellular adenosine production by ecto-5′-nucleotidase protects during murine hepatic ischemic preconditioning. Gastroenterology 2008. 135: 17391750 e1733.
  • 17
    Eckle, T., Krahn, T., Grenz, A., Kohler, D., Mittelbronn, M., Ledent, C., Jacobson, M. A. et al., Cardioprotection by ecto-5′-nucleotidase (CD73) and A2B adenosine receptors. Circulation 2007. 115: 15811590.
  • 18
    Kiss, J., Yegutkin, G. G., Koskinen, K., Savunen, T., Jalkanen, S. and Salmi, M., IFN-beta protects from vascular leakage via up-regulation of CD73. Eur. J. Immunol. 2007. 37: 33343338.
  • 19
    Mills, J. H., Thompson, L. F., Mueller, C., Waickman, A. T., Jalkanen, S., Niemela, J., Airas, L. and Bynoe, M. S., CD73 is required for efficient entry of lymphocytes into the central nervous system during experimental autoimmune encephalomyelitis. Proc. Natl. Acad. Sci. USA 2008. 105: 93259330.
  • 20
    Spychala, J., Tumor-promoting functions of adenosine. Pharmacol. Ther. 2000. 87: 161173.
  • 21
    Wang, L., Zhou, X., Zhou, T., Ma, D., Chen, S., Zhi, X., Yin, L. et al., Ecto-5′-nucleotidase promotes invasion, migration and adhesion of human breast cancer cells. J. Cancer Res. Clin. Oncol. 2008. 134: 365372.
  • 22
    Mosser, D. M. and Edwards, J. P., Exploring the full spectrum of macrophage activation. Nat. Rev. Immunol. 2008. 8: 958969.
  • 23
    Gordon, S. and Martinez, F. O., Alternative activation of macrophages: mechanism and functions. Immunity 2010. 32: 593604.
  • 24
    Biswas, S. K. and Mantovani, A., Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat. Immunol. 2010. 11: 889896.
  • 25
    Yamashita, Y., Hooker, S. W., Jiang, H., Laurent, A. B., Resta, R., Khare, K., Coe, A. et al., CD73 expression and fyn-dependent signaling on murine lymphocytes. Eur. J. Immunol. 1998. 28: 29812990.
  • 26
    Yang, L., Kobie, J. J. and Mosmann, T. R., CD73 and Ly-6A/E distinguish in vivo primed but uncommitted mouse CD4 T cells from type 1 or type 2 effector cells. J. Immunol. 2005. 175: 64586464.
  • 27
    Montesinos, M. C., Shaw, J. P., Yee, H., Shamamian, P. and Cronstein, B. N., Adenosine A(2A) receptor activation promotes wound neovascularization by stimulating angiogenesis and vasculogenesis. Am. J. Pathol. 2004. 164: 18871892.
  • 28
    Nair, M. G., Du, Y., Perrigoue, J. G., Zaph, C., Taylor, J. J., Goldschmidt, M., Swain, G. P. et al., Alternatively activated macrophage-derived RELM-alpha is a negative regulator of type 2 inflammation in the lung. J. Exp. Med. 2009. 206: 937952.
  • 29
    Asano, K., Nabeyama, A., Miyake, Y., Qiu, C. H., Kurita, A., Tomura, M., Kanagawa, O. et al., CD169-positive macrophages dominate antitumor immunity by crosspresenting dead cell-associated antigens. Immunity 2011. 34: 8595.
  • 30
    Qian, B. Z. and Pollard, J. W., Macrophage diversity enhances tumor progression and metastasis. Cell 2010. 141: 3951.
  • 31
    Nishikawa, H. and Sakaguchi, S., Regulatory T cells in tumor immunity. Int. J. Cancer 2010. 127: 759767.
  • 32
    Mantovani, A., The growing diversity and spectrum of action of myeloid-derived suppressor cells. Eur. J. Immunol. 2010. 40: 33173320.
  • 33
    Sica, A., Porta, C., Riboldi, E. and Locati, M., Convergent pathways of macrophage polarization: The role of B cells. Eur. J. Immunol. 2010. 40: 21312133.
  • 34
    Martinez, F. O., Gordon, S., Locati, M. and Mantovani, A., Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene expression. J. Immunol. 2006. 177: 73037311.
  • 35
    Nalos, M., Huang, S., Sluyter, R., Khan, A., Santner-Nanan, B., Nanan, R. and McLean, A. S., “Host tissue damage” signal ATP impairs IL-12 and IFNgamma secretion in LPS stimulated whole human blood. Intensive Care Med. 2008. 34: 18911897.
  • 36
    Shankaran, V., Ikeda, H., Bruce, A. T., White, J. M., Swanson, P. E., Old, L. J. and Schreiber, R. D., IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001. 410: 11071111.
  • 37
    Ohtsuka, T., Changelian, P. S., Bouis, D., Noon, K., Harada, H., Lama, V. N. and Pinsky, D. J., Ecto-5′-nucleotidase (CD73) attenuates allograft airway rejection through adenosine 2A receptor stimulation. J. Immunol. 2010. 185: 13211329.
  • 38
    Alam, M. S., Kurtz, C. C., Rowlett, R. M., Reuter, B. K., Wiznerowicz, E., Das, S., Linden, J. et al., CD73 is expressed by human regulatory T helper cells and suppresses proinflammatory cytokine production and Helicobacter felis-induced gastritis in mice. J. Infect. Dis. 2009. 199: 494504.
  • 39
    Barnholt, K. E., Kota, R. S., Aung, H. H. and Rutledge, J. C., Adenosine blocks IFN-gamma-induced phosphorylation of STAT1 on serine 727 to reduce macrophage activation. J. Immunol. 2009. 183: 67676777.
  • 40
    Pelegrin, P. and Surprenant, A., Dynamics of macrophage polarization reveal new mechanism to inhibit IL-1beta release through pyrophosphates. EMBO J. 2009. 28: 21142127.
  • 41
    Pellegatti, P., Raffaghello, L., Bianchi, G., Piccardi, F., Pistoia, V. and Di Virgilio, F., Increased level of extracellular ATP at tumor sites: in vivo imaging with plasma membrane luciferase. PLoS One 2008. 3: e2599.
  • 42
    Ghiringhelli, F., Apetoh, L., Tesniere, A., Aymeric, L., Ma, Y., Ortiz, C., Vermaelen, K. et al., Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat. Med. 2009. 15: 11701178.
  • 43
    Weigert, A. and Brune, B., Nitric oxide, apoptosis and macrophage polarization during tumor progression. Nitric Oxide 2008. 19: 95102.
  • 44
    Ekmekcioglu, S., Ellerhorst, J., Smid, C. M., Prieto, V. G., Munsell, M., Buzaid, A. C. and Grimm, E. A., Inducible nitric oxide synthase and nitrotyrosine in human metastatic melanoma tumors correlate with poor survival. Clin. Cancer Res. 2000. 6: 47684775.
  • 45
    Jackson, S. W., Hoshi, T., Wu, Y., Sun, X., Enjyoji, K., Cszimadia, E., Sundberg, C. and Robson, S. C., Disordered purinergic signaling inhibits pathological angiogenesis in cd39/Entpd1-null mice. Am. J. Pathol. 2007. 171: 13951404.
  • 46
    Sun, X., Wu, Y., Gao, W., Enjyoji, K., Csizmadia, E., Muller, C. E., Murakami, T. and Robson, S. C., CD39/ENTPD1 expression by CD4+Foxp3+regulatory T cells promotes hepatic metastatic tumor growth in mice. Gastroenterology 2010. 139: 10301040.
  • 47
    Wu, Y., Sun, X., Kaczmarek, E., Dwyer, K. M., Bianchi, E., Usheva, A. and Robson, S. C., RanBPM associates with CD39 and modulates ecto-nucleotidase activity. Biochem. J. 2006. 396: 2330.
  • 48
    Chen, Y., Corriden, R., Inoue, Y., Yip, L., Hashiguchi, N., Zinkernagel, A., Nizet, V. et al., ATP release guides neutrophil chemotaxis via P2Y2 and A3 receptors. Science 2006. 314: 17921795.
  • 49
    Stagg, J., Divisekera, U., McLaughlin, N., Sharkey, J., Pommey, S., Denoyer, D., Dwyer, K. M. and Smyth, M. J., Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis. Proc. Natl. Acad. Sci. USA 2010. 107: 15471552.
  • 50
    Jin, D., Fan, J., Wang, L., Thompson, L. F., Liu, A., Daniel, B. J., Shin, T. et al., CD73 on tumor cells impairs antitumor T-cell responses: a novel mechanism of tumor-induced immune suppression. Cancer Res. 2010. 70: 22452255.
  • 51
    Synnestvedt, K., Furuta, G. T., Comerford, K. M., Louis, N., Karhausen, J., Eltzschig, H. K., Hansen, K. R. et al., Ecto-5′-nucleotidase (CD73) regulation by hypoxia-inducible factor-1 mediates permeability changes in intestinal epithelia. J. Clin. Invest. 2002. 110: 9931002.
  • 52
    Marttila-Ichihara, F., Turja, R., Miiluniemi, M., Karikoski, M., Maksimow, M., Niemela, J., Martinez-Pomares, L. et al., Macrophage mannose receptor on lymphatics controls cell trafficking. Blood 2008. 112: 6472.
  • 53
    Marttila-Ichihara, F., Auvinen, K., Elima, K., Jalkanen, S. and Salmi, M., Vascular adhesion protein-1 enhances tumor growth by supporting recruitment of Gr-1+CD11b+myeloid cells into tumors. Cancer Res. 2009. 69: 78757883.
  • 54
    Yegutkin, G. G., Hytonen, J., Samburski, S. S., Yrjanainen, H., Jalkanen, S. and Viljanen, M. K., Disordered lymphoid purine metabolism contributes to the pathogenesis of persistent Borrelia garinii infection in mice. J. Immunol. 2010. 184: 51125120.
  • 55
    Marttila-Ichihara, F., Castermans, K., Auvinen, K., Oude Egbrink, M. G., Jalkanen, S., Griffioen, A. W. and Salmi, M., Small-molecule inhibitors of vascular adhesion protein-1 reduce the accumulation of myeloid cells into tumors and attenuate tumor growth in mice. J. Immunol. 2010. 184: 31643173.
  • 56
    Zimmermann, H., 5′-nucleotidase: molecular structure and functional aspects. Biochem. J. 1992. 285: 345365.